entertainment -WSS

entertainment

author：knowledge 2025-09-30 20:27:11 - browse：43765

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA drug safety: Singulair case shows systemic surveillance flaws

hotspot

WSS

General Catalyst, Summa Health deal will turn on physician buy

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

SAMSHA loosens regulations on methadone treatment centers

Apple Vision Pro: A first look at health apps on the new VR headset

Abridge raises $150m as clinical notes automation market heats up

Medicare Advantage enrollment hits roughly 33.4 million

hotspot

entertainment

leisure time

Hollywood unions extend contract negotiations for actors

Medicare Advantage enrollment hits roughly 33.4 million

Walensky prepares to leave CDC — and Congress — behind

Medicare drug price negotiation’s day in court

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Covid misinformation case heads to Supreme Court

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ukraine seeks to reclaim its role as a hub for clinical trials

Hepatitis C has a cure — but many Americans still lack access to it

In 'major milestone,' FDA approves first cell therapy for solid tumors

explore

Cognito secures funding to test medical device for Alzheimer's

A $475,000 price tag for a new cancer drug: crazy or meh?

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Congress may force more Covid

Researchers tackle phage therapy hurdles for wider adoption

Quicker fix for pulse oximeters urged during FDA public meeting

Wikipedia

entertainment

hotspot

focus